Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01411345 · ClinicalTrials.gov registry record · NA

MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial

A NA study of Prostate Cancer and Prostate Adenocarcinoma, sponsored by University of Miami.

Active
Registry status
NA
Development phase
37
Enrollment target
1
Study location

NCT01411345 is a NA study of Prostate Cancer and Prostate Adenocarcinoma that is active but no longer recruiting, run by University of Miami. The registered enrollment target is 37 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01411345, a NA study of Prostate Cancer and Prostate Adenocarcinoma, is active but no longer recruiting, sponsored by University of Miami.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
37 participants
Enrollment target
1
Study location

Study Summary

1. The investigators hypothesize that increasing radiation dose to the functional MRI-defined lesion in the prostate bed will result in an improved initial complete response (reduction in prostate-specific antigen (PSA) to \< 0.1 ng/mL), which is related to long-term outcome biochemically. 2. Biomarker expression levels differ in the DCE-MRI enhancing and non-enhancing tumor regions (when applicable). 3. 10-15% of men undergoing RT have free circulating DNA (fcDNA) or tumor cells (CTC) that are related to an adverse treatment outcome. 4. Prostate cancer-related anxiety will be reduced in the MRI targeted SRT arm, because the patients will be aware that the dominant tumor will be targeted with higher radiation dose (compared to those pts who were treated on standard arm prior to its closure).

Interventions

  • RADIATION Standard Salvage Radiation Treatment (SSRT)
  • RADIATION Mapped Tumor Salvage RT (MTSRT)

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2012-07-12
Est. Completion 2028-02-13
Phase NA

Sponsor

University of Miami

721 total trials

What the Registry Record Tells You About NCT01411345

The ClinicalTrials.gov registry entry for NCT01411345 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Standard Salvage Radiation Treatment (SSRT) is the first listed.

NCT01411345 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT01411345 about?

NCT01411345 is a clinical study titled "MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial". 1. The investigators hypothesize that increasing radiation dose to the functional MRI-defined lesion in the prostate bed will result in an improved initial complete response (reduction in prostate-specific antigen (PSA) to \< 0.1 ng/mL), which is related to long-term outcome biochemically. 2. Biomar...

What is the current status of trial NCT01411345?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 37 participants. The study started on 2012-07-12. Estimated completion is 2028-02-13.

What conditions does trial NCT01411345 study?

This clinical trial studies the following conditions: Prostate Cancer, Prostate Adenocarcinoma.

What interventions are being tested in trial NCT01411345?

The interventions under investigation include: Standard Salvage Radiation Treatment (SSRT) (RADIATION), Mapped Tumor Salvage RT (MTSRT) (RADIATION).

Who is sponsoring clinical trial NCT01411345?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01411345 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.